22 January 2025

CORXEL Announces Upcoming Presentation at the International Stroke Conference 2025 on JX10 Improving Neurological Outcomes in Acute Lacunar Infarct

  • Novel thrombolytic with Anti-inflammatory properties (JX10) improves neurological outcomes in Acute Lacunar Infarct up to 12 hours after onset

NEW JERSEY/SHANGHAI, January 22, 2025 – Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today announced an upcoming presentation regarding JX10 at the International Stroke Conference (ISC) on February 5th 2025. 

In the prior Phase 2 clinical trial conducted in Japan, patients treated with JX10 had significantly improved clinical outcomes (proportion of patients with no or minimal neurological deficits) at 90 days, compared to placebo. Results of this Phase 2 study were recently published in Stroke1, including an illustration of JX10's proposed mechanism on the cover of the December 2024 print version. 

 

Oral Abstract Session                                                                                                                     

Title: Novel thrombolytic with Anti-inflammatory properties (JX10) improves neurological outcomes in Acute Lacunar Infarct up to 12 hours after onset                                                                 

Presenter: Edmond Chen, MD – CMO at CORXEL Pharmaceuticals                       

Date: February 5th 2025                                                                                                               

Session Title: Acute Treatment: Systemic Thrombolysis and Cerebroprotection Oral Abstracts II

Session Time: 3:30pm-4:30pm (Pacific)                                                                                     

Location:  Los Angeles Convention Center, Room 408AB 

Additional information

JX10 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit  more patients over current standard of care by extending the otherwise short treatment window of 4.5hrs after symptom onset. 

In the prior Phase 2 clinical trial conducted in Japan, patients treated with JX10 had significantly improved clinical outcomes (proportion of patients with no or minimal neurological deficits) at 90 days, compared to placebo.  This was further supported by safety and angiographic findings. CORXEL is currently initiating a global registrational study to further evaluate the efficacy and safety of JX10 in Acute Ischemic Stroke with late presentations. 

CORXEL, is a leading biotech company headquartered in US and China focused on developing innovative cardiometabolic therapies globally. CORXEL was founded in 2019 and has been committed to bringing innovative science and medicines to underserved patients around the world. With a strong and further developing asset pipeline, industry leading talent, and patient-centric focus, CORXEL is dedicated to delivering a meaningful and lasting impact on patients.   

The portfolio of CORXEL consists of 3 assets with global rights and 2 assets with Greater China rights in late-stage clinical development. The portfolio with global rights covers CX11 for obesity and diabetes, JX10 for acute ischemic stroke (AIS) and JX09 for hypertension, while the portfolio with Greater China rights includes Etripamil and LNZ100.   

For further information about CORXEL, please visit www.corxelbio.com    

Contacts:

Media Contact

Corxel Pharmaceuticals

References:

1. Niizuma, Kuniyasu et al. Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke. Stroke. 2024;55;12. https://doi.org/10.1161/STROKEAHA.124.048464